Taro Pharmaceutical Industries Ltd
NYSE:TARO
Taro Pharmaceutical Industries Ltd
Income from Continuing Operations
Taro Pharmaceutical Industries Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Income from Continuing Operations
$45.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-18%
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Income from Continuing Operations
-$617m
|
CAGR 3-Years
47%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
I
|
InterCure Ltd
TASE:INCR
|
Income from Continuing Operations
₪17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
Mediwound Ltd
NASDAQ:MDWD
|
Income from Continuing Operations
-$6.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Income from Continuing Operations
-₪8.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Income from Continuing Operations
-₪5.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Taro Pharmaceutical Industries Ltd's Income from Continuing Operations?
Income from Continuing Operations
45.6m
USD
Based on the financial report for Dec 31, 2023, Taro Pharmaceutical Industries Ltd's Income from Continuing Operations amounts to 45.6m USD.
What is Taro Pharmaceutical Industries Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-18%
Over the last year, the Income from Continuing Operations growth was -1%.